Drug Trial Radar · NCT04287985
Safety and Efficacy Study of VIS649 for IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Jul 20, 2020
Primary completion
May 19, 2023
Study completion Jun 18, 2023
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Feb 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Conditions
- Immunoglobulin A Nephropathy
- Glomerular Disease
- IgAN
Interventions
Dose-PlaceboDrug
Unit Dose Strength - 0.9%.
Low Dose-VIS649Drug
Dose Level = Low
Medium Dose-VIS649Drug
Dose Level = Medium
High Dose-VIS649Drug
Dose Level = High
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events Graded by SeverityTime frame: Baseline to End of Study (16 months)
- Changes From Baseline in Clinical Laboratory TestsTime frame: Baseline to End of Study (16 months)
- Clinically Meaningful Changes From Baseline in Vital SignsTime frame: Baseline to End of Study (16 months)
- Clinically Significant Physical ExaminationsTime frame: Baseline to End of Study (16 months)
- Change From Baseline in uPCR: Month 12Time frame: 12 months
Locations
93 sites in 15 countries. Site status is shown where the registry gives one.
Visterra Investigational Site
Birmingham, Alabama
Visterra Investigational Site
Los Angeles, California
Visterra Investigational Site
Oxnard, California
Visterra Investigational Site
Palo Alto, California
Visterra Investigational Site
Stanford, California
Visterra Investigational Site
Denver, Colorado
Visterra Investigational Site
Lawrenceville, Georgia
Visterra Investigational Site
Baton Rouge, Louisiana
Visterra Investigational Site
New Orleans, Louisiana
Visterra Investigational Site
Baltimore, Maryland
Visterra Investigational Site
Tupelo, Mississippi
Visterra Investigational Site
New York, New York
Visterra Investigational Site
Chapel Hill, North Carolina
Visterra Investigational Site
Columbus, Ohio
Visterra Investigational Site
Bethlehem, Pennsylvania
Visterra Investigational Site
Houston, Texas
Visterra Investigational Site
Houston, Texas
Visterra Investigational Site
New Lambton Heights, New South Wales, Australia
Visterra Investigational Site
Saint Leonards, New South Wales, Australia
Visterra Investigational Site
Nambour, Queensland, Australia
Visterra Investigational Site
Nedlands, Western Australia, Australia
Visterra Investigational Site
Calgary, Alberta, Canada
Visterra Investigational Site
Brampton, Ontario, Canada
Visterra Investigational Site
Montreal, Quebec, Canada
Visterra Investigational Site
Hong Kong, Hong Kong
Visterra Investigational Site
Kowloon, Hong Kong
Visterra Investigational Site
Tsuen Wan, Hong Kong
Visterra Investigational Site
Hong Kong, HK, Hong Kong
Visterra Investigational Site
Chandigarh, Chandigarh, India
Visterra Investigational Site
Bangalore, Karnataka, India
Visterra Investigational Site
Bengaluru, Karnataka, India
Visterra Investigational Site
Manipal, Karnataka, India
Visterra Investigational Site
Kozhikode, Kerala, India
Visterra Investigational Site
Thiruvananthapuram, Kerala, India
Visterra Investigational Site
New Delhi, National Capital Territory of Delhi, India
Visterra Investigational Site
Vellore, Tamil Nadu, India
Visterra Investigational Site
Hyderabad, Telangana, India
Visterra Investigational Site
Hyderabad, Telangana, India
Visterra Investigational Site
Raebareli, Uttar Pradesh, India
Visterra Investigational Site
Ashikaga-Shi, Japan
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.